🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT04688593
Recruiting Observational

Clinical and Functional Outcome of the MobileLink Acetabular Cup System in the Short-, Mid-, and Longterm Follow-up

NCT04688593 · tracked via the Priya Life Science UK tracker
Sponsor
Waldemar Link GmbH & Co. KG
Phase
Observational
Started
2021-05-04
Last updated
2024-01-25

Condition(s) studied

Osteoarthritis, HipHip OsteoarthritisProsthesis SurvivalProsthesis Failure

Investigational drug(s) / intervention(s)

MobileLink

MobileLink: Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.

Study summary

The implantation of artificial hip joints is one of the most frequently performed surgeries. Normally, patients are very satisfied with the results.

The MobileLink hip prosthesis system is a CE marked medical device. This means the the safety and performance of the prosthesis ist approved. Aim of the study is to collect clinical data about the outcome of the MobileLink hip prosthesis system under routine condition and to determine the satisfaction of the patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Implantation of a MobileLink acetabular cup system and a femoral stem manufactured by Waldemar Link * Age ≥ 18 years * Fully signed patient informed cons Exclusion Criteria: * Revisions * Body Mass Index (BMI) ≥ 40 kg/m² * Patient who is foreseeable not able to understand the study and the study-related circumstances * Patients who is foreseeable non-compliant to the treatment and the follow-ups * Pregnant or breast-feeding women * Prisoner

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Lubinus Stiftung Kiel Germany Recruiting
NHS FIFE Victoria Hospital Kirkcaldy United Kingdom Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04688593 on ClinicalTrials.gov ↗ ← All trials in the UK